PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS
Publication
, Conference
Peters, K; Kirkpatrick, J; Batinic-Haberle, I; Affronti, M; Woodring, S; Iden, D; Panta, S; Lipp, E; Healy, P; Herndon, J; Spasojevic, I ...
Published in: NEURO-ONCOLOGY
November 5, 2018
ACTR-28
Duke Scholars
Published In
NEURO-ONCOLOGY
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 5, 2018
Volume
20
Issue
suppl. 6; abstr QOLP-13
Start / End Page
1vi7 / vi17
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Peters, K., Kirkpatrick, J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., … Crapo, J. (2018). PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. In NEURO-ONCOLOGY (Vol. 20, pp. 1vi7-vi17). New Orleans, LA: OXFORD UNIV PRESS INC. https://doi.org/10.1093/neuonc/noy148.061
Peters, Katherine, John Kirkpatrick, Ines Batinic-Haberle, Mary Affronti, Sarah Woodring, Deborah Iden, Sujata Panta, et al. “PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS.” In NEURO-ONCOLOGY, 20:1vi7-vi17. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.061.
Peters K, Kirkpatrick J, Batinic-Haberle I, Affronti M, Woodring S, Iden D, et al. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 1vi7-vi17.
Peters, Katherine, et al. “PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS.” NEURO-ONCOLOGY, vol. 20, no. suppl. 6; abstr QOLP-13, OXFORD UNIV PRESS INC, 2018, pp. 1vi7-vi17. Manual, doi:10.1093/neuonc/noy148.061.
Peters K, Kirkpatrick J, Batinic-Haberle I, Affronti M, Woodring S, Iden D, Panta S, Lipp E, Healy P, Herndon J, Spasojevic I, Penchev S, Gad S, Siberstein D, Johnson M, Randazzo D, Desjardins A, Friedman H, Ashley D, Crapo J. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 1vi7-vi17.
Published In
NEURO-ONCOLOGY
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 5, 2018
Volume
20
Issue
suppl. 6; abstr QOLP-13
Start / End Page
1vi7 / vi17
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences